PROCEPT BioRobotics Timeline

Events

• 2026-08-04 - Market Signal - PROCEPT BioRobotics reports $94.5 million Q2 revenue - The company delivered 65 HYDROS systems during the quarter. U.S. procedure volume exceeded 13,100, representing 21% year-on-year growth. PROCEPT maintained full-year revenue guidance of $390 million to $410 million. - source: globenewswire.com
• 2024-08-20 - Regulatory - PROCEPT BioRobotics receives FDA clearance for HYDROS robotic system - PROCEPT BioRobotics received FDA 510(k) clearance for HYDROS, its next-generation robotic system for Aquablation therapy. HYDROS extends the company''s urology robotics platform with image-guided planning and treatment workflow updates. The regulatory… - source: ir.procept-biorobotics.com
• 2021-09-15 - Market Signal - PROCEPT BioRobotics prices Nasdaq IPO - PROCEPT expected its common stock to begin trading on the Nasdaq Global Market on September 15, 2021. The IPO was priced at $25.00 per share. The company offered all shares in the upsized offering. - source: ir.procept-biorobotics.com
• 2019-11-06 - Regulatory - CMS grants AquaBeam transitional pass-through payment status - The payment status applied through the 2020 outpatient prospective payment system. AquaBeam delivers image-guided robotic waterjet removal of prostate tissue for BPH. The reimbursement decision supported use of the exact system in outpatient care. - source: ir.procept-biorobotics.com
• 2018-02-21 - Funding - PROCEPT BioRobotics raises $118 million equity financing - Equity financing: USD 118,000,000. Viking Global Investors led or co-led the financing. PROCEPT BioRobotics raised $118 million in equity financing to support worldwide commercialisation of Aquablation therapy and the AquaBeam surgical robotics system. - source: ir.procept-biorobotics.com